Loading...
•
Jun 30, 2024
Treace Q2 2024 Earnings Report
Reported financial results, with revenue increasing by 6% compared to the same period in 2023.
Key Takeaways
Treace Medical Concepts reported a 6% increase in revenue for the second quarter of 2024, reaching $44.5 million. The company's gross margin was 80.2%. The company is reaffirming full-year 2024 revenue guidance of $201 million to $211 million.
Revenue of $44.5 million in second quarter 2024 increased 6% over same period in 2023
Gross margin of 80.2% in second quarter 2024
Patent portfolio expands to 65 granted U.S. patents, with an additional 22 granted patents worldwide and 84 pending U.S. patent applications
Reaffirming full-year 2024 revenue guidance of $201 million to $211 million, representing growth of 7% to 13%, compared to full-year 2023.
Forward Guidance
The Company is reaffirming full-year 2024 revenue guidance of $201 million to $211 million, representing growth of 7% to 13%, compared to full-year 2023. The Company continues to expect Adjusted EBITDA to improve approximately 50% compared to full-year 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...